Insider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 9 Shares of Stock

GlaxoSmithKline plc (LON:GSK) insider Patrick Vallance bought 9 shares of the stock in a transaction dated Friday, February 9th. The stock was bought at an average price of GBX 1,298 ($17.93) per share, with a total value of £116.82 ($161.40).

Patrick Vallance also recently made the following trade(s):

  • On Monday, December 18th, Patrick Vallance sold 20,000 shares of GlaxoSmithKline stock. The shares were sold at an average price of GBX 1,310 ($18.10), for a total value of £262,000 ($361,978.45).

GlaxoSmithKline plc (GSK) opened at GBX 1,290.80 ($17.83) on Thursday. GlaxoSmithKline plc has a 1-year low of GBX 1,235.20 ($17.07) and a 1-year high of GBX 1,724.50 ($23.83). The company has a market capitalization of $64,000.00 and a P/E ratio of 4,163.87.

The company also recently announced a dividend, which will be paid on Thursday, April 12th. Shareholders of record on Thursday, February 22nd will be issued a dividend of GBX 23 ($0.32) per share. This represents a yield of 1.78%. The ex-dividend date of this dividend is Thursday, February 22nd. This is an increase from GlaxoSmithKline’s previous dividend of $19.00.

A number of equities research analysts have recently issued reports on GSK shares. Morgan Stanley set a GBX 1,600 ($22.11) target price on GlaxoSmithKline and gave the company a “sell” rating in a research note on Wednesday, October 18th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a research note on Monday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 1,570 ($21.69) target price on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Beaufort Securities reiterated a “buy” rating and issued a GBX 1,800 ($24.87) target price on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Finally, UBS Group set a GBX 1,600 ($22.11) target price on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of GBX 1,540.45 ($21.28).

TRADEMARK VIOLATION WARNING: “Insider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 9 Shares of Stock” was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/02/15/insider-buying-glaxosmithkline-plc-gsk-insider-acquires-9-shares-of-stock.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply